Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to 9267.68%.

  • Dianthus Therapeutics' EBITDA Margin fell 81417100.0% to 9267.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 4121.6%, marking a year-over-year decrease of 28768600.0%. This contributed to the annual value of 1361.83% for FY2024, which is 1720400.0% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' EBITDA Margin is 9267.68%, which was down 81417100.0% from 16477.2% recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' EBITDA Margin peaked at 676.39% during Q3 2022, and registered a low of 16477.2% during Q2 2025.
  • Moreover, its 4-year median value for EBITDA Margin was 1581.46% (2024), whereas its average is 3247.59%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 4701400bps in 2024, then plummeted by -155315800bps in 2025.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' EBITDA Margin stood at 861.87% in 2022, then tumbled by -186bps to 2467.61% in 2023, then grew by 11bps to 2188.16% in 2024, then tumbled by -324bps to 9267.68% in 2025.
  • Its EBITDA Margin was 9267.68% in Q3 2025, compared to 16477.2% in Q2 2025 and 2523.39% in Q1 2025.